Short interest in Raptor Pharmaceuticals (NASDAQ:RPTP) increased by 6% over the last two months, in tandem with the stock's rise to $6.28, which has since pressured shares into a downward move. But the move back to the $4 range has …
Leerink Partners analyst Joseph Schwartz reiterating an Outperform rating on Raptor Pharmaceuticals ... RPTP), saying …
RPTP), “lowering sales estimates with US market saturation and slow EU launch.” The specialists reiterated an Underperform rating and a $7 price target on the stock. The company is scheduled to report earnings on Thursday after …
Raptor Pharmaceuticals Corp. (RPTP) saw a big move in the last trading session, as the company’s shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. …
My fellow Minyanville Professor and co-founder of our firm ... Today, however, I want to focus on Raptor Pharmaceuticals (RPTP). Raptor's lead drug is DR Cysteamine for treatment of the orphan disease nephropathic cystinosis. Cystinosis …
We believe the market is currently massively overvaluing RPTP due to errors in analysis and certain critical factors that analysts covering the stock are not taking into account. These include the following items: a. Analysts are grossly …
--(BUSINESS WIRE)--Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of …
The average earnings surprise over the last four quarters is a positive 4.56%. The Earnings ESP for Raptor Pharmaceuticals Corp. RPTP is +11.11% and it carries a Zacks Rank #3. The company will be reporting second …